Gene expression and polymorphisms of DNA repair enzymes: Cancer susceptibility and response to chemotherapy

Clinical Lung Cancer

Volumn 8, Issue 6, 2007, Pages 369-375

  Camps, Carlos ^a   Sirera, Rafael ^a   Iranzo, Vega ^a   Tarón, Miquel ^b   Rosell, Rafael ^b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

Author keywords

Cisplatin; Single nucleotide polymorphisms; Squamous cell carcinoma

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; GEMCITABINE; PLATINUM; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

BLADDER CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER SCREENING; CANCER SURVIVAL; CANCER SUSCEPTIBILITY; DNA POLYMORPHISM; DOSE RESPONSE; DRUG MECHANISM; ESOPHAGUS CANCER; GENE EXPRESSION; GENETIC ANALYSIS; HEREDITY; HUMAN; LEUKEMIA; LUNG NON SMALL CELL CANCER; MEDICAL EDUCATION; PATIENT SELECTION; REVIEW; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 34250334723     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.n.017     Document Type: Review

References (90)

1. Wang D, Lippard SJ. Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 2005; 4:307-320.
2. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:1513-1530.
3. Wood RD, Mitchell M, Sgouros J, et al. Human DNA repair genes. Science 2001; 291:1284-1289.
4. Cleaver JE. Cancer in xeroderma pigmentosum and related disorders of DNA repair. Nat Rev Cancer 2005; 5:564-573.
5. Friedberg EC. How nucleotide excision repair protects against cancer. Nat Rev Cancer 2001; 1:22-33.
6. Ljungman M, Lane DP. Transcription - guarding the genome by sensing DNA damage. Nat Rev Cancer 2004; 4:727-737.
7. Modrich P. Mechanisms in eukaryotic mismatch repair. J Biol Chem 2006; 281:30305-30309.
8. Sieber OM, Heinimann K, Tomlinson IP. Genomic instability-the engine of tumorigenesis? Nat Rev Cancer 2003; 3:701-708.
9. Madhusudan S, Middleton MR. The emerging role of DNA repair proteins as predictive, prognostic and therapeutic targets in cancer. Cancer Treat Rev 2005; 31:603-617.
10. Kiyohara C, Otsu A, Shirakawa T, et al. Genetic polymorphisms and lung cancer susceptibility: a review. Lung Cancer 2002; 37:241-256.
11. Risinger MA, Groden J. Crosslinks and crosstalk: human cancer syndromes and DNA repair defects. Cancer Cell 2004; 6:539-545.
12. Berwick M, Vineis P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J Natl Cancer Inst 2000; 92:874-897.
13. Neumann AS, Sturgis EM, Wei Q. Nucleotide excision repair as a marker for susceptibility to tobacco-related cancers: a review of molecular epidemiological studies. Mol Carcinog 2005; 42:65-92.
14. Yamaguchi S, Shinmura K, Saitoh T, et al. A single nucleotide polymorphism at the splice donor site of the human MYH base excision repair genes results in reduced translation efficiency of its transcripts. Genes Cells 2002; 7:461-474.
15. Yang G, Scherer SJ, Shell SS, et al. Dominant effects of an Msh6 missense mutation on DNA repair and cancer susceptibility. Cancer Cell 2004; 6:139-150.
16. Wei Q, Cheng L, Amos CI, et al. Repair of tobacco carcinogen-induced DNA adducts and lung cancer risk: a molecular epidemiologic study. J Natl Cancer Inst 2000; 92:1764-1772.
17. Spitz MR, Wu X, Wang Y, et al. Modulation of nucleotide excision repair capacity by XPD polymorphisms in lung cancer patients. Cancer Res 2001; 61:1354-1357.
18. Paz-Elizur T, Krupsky M, Blumenstein S, et al. DNA repair activity for oxidative damage and risk of lung cancer. J Natl Cancer Inst 2003; 95:1312-1319.
19. Le Marchand L, Donlon T, Lum-Jones A, et al. Association of the hOGG1 Ser326Cys polymorphism with lung cancer risk. Cancer Epidemiol Biomarkers Prev 2002; 11:409-412.
20. Butkiewicz D, Rusin M, Enewold L, et al. Genetic polymorphisms in DNA repair genes and risk of lung cancer. Carcinogenesis 2001; 22:593-597.
21. Cheng L, Spitz MR, Hong WK, et al. Reduced expression levels of nucleotide excision repair genes in lung cancer: a case-control analysis. Carcinogenesis 2000; 21:1527-1530.
22. Duell EJ, Wiencke JK, Cheng TJ, et al. Polymorphisms in the DNA repair genes XRCCl and ERCC2 and biomarkers of DNA damage in human blood mononuclear cells. Carcinogenesis 2000; 21:965-971.
23. Ratnasinghe D, Yao SX, Tangrea JA, et al. Polymorphisms of die DNA repair gene XRCC1 and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2001; 10:119-123.
24. Demokan S, Demir D, Suoglu Y, et al. Polymorphisms of the XRCC1 DNA repair gene in head and neck cancer. Pathol Oncol Res 2005; 11:22-25.
25. Chen S, Tang D, Xue K, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of lung cancer in a Chinese population. Carcinogenesis 2002; 23:1321-1325.
26. Hou SM, Fait S, Angelini S, et al. The XPD variant alleles are associated with increased aromatic DNA adduct level and lung cancer risk. Carcinogenesis 2002; 23:599-603.
27. Ryk C, Kumar R, Thirumaran RK, et al. Polymorphisms in the DNA repair genes XRCC1, APEX1, XRCC3 and NBS1, and the risk for lung cancer in never- and ever-smokers. Lung Cancer 2006; 54:285-292.
28. Park JY, Park SH, Choi JE, et al. Polymorphisms of the DNA repait gene xeroderma pigmentosum group A and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:993-997.
29. Sakiyama T, Kohno T, Mimaki S, et al. Association of amino acid substitution polymorphisms in DNA repair genes TP53, POLI, REV1 and LIG4 with lung cancer risk. Int J Cancer 2005; 114:730-737.
30. Zhou W, Liu G, Miller DP, et al. Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk. Cancer Epidemiol Biomarkers Prev 2003; 12:359-365.
31. Ito H, Matsuo K, Hamajima N, et al. Gene-environment infractions between the smoking habit and polymorphisms in the DNA repair genes, APE1 Asp148Glu and XRCC1 Arg399Gln, in Japanese lung cancer risk. Carcinogenesis 2004; 25:1395-1401.
32. Zhou W, Liu G, Miller DP, et al. Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer. Cancer Res 2002; 62:1377-1381.
33. Hu Z, Wang Y, Wang X, et al. DNA repair gene XPC genotypes/haplotypes and risk of lung cancer in a Chinese population. Int J Cancer 2005; 115:478-483.
34. Park JY, Lee SY, Jeon HS, et al. Polymorphism of the DNA repair gene XRCC1 and risk of primary lung cancer. Cancer Epidemiol Biomarkers Prev 2002; 11:23-27.
35. Zhou W, Liu G, Park S, et al. Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer. Cancer Epidemiol Biomarkers Prev 2005; 14:491-496.
36. Sturgis EM, Dahlstrom KR, Spitz MR, et al. DNA repair gene ERCC1 and ERCC2/XPD polymorphisms and risk of squamous cell carcinoma of the head and neck. Arch Otolaryngol Head Neck Surg 2002; 128:1084-1088.
37. Sturgis EM, Castillo EJ, Li L, et al. Polymorphisms of DNA repair gene XRCC1 in squamous cell carcinoma of the head and neck. Carcinogenesis 1999; 20:2125-2129.
38. Tae K, Lee HS, Park BJ, et al. Association of DNA repair gene XRCC1 polymorphisms with head and neck cancer in Korean population. Int J Cancer 2004; 111:805-808.
39. Hirata H, Hinoda Y, Tanaka Y, et al. Polymorphisms of DNA repair genes are risk factors for prostate cancer. Eur J Cancer 2006; 43:231-237.
40. Rybicki BA, Conti DV, Moreira A, et al. DNA repair gene XRCC1 and XPD polymorphisms and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev 2004; 13:23-29.
41. Xu J, Zheng SL, Turner A, et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res 2002; 62:2253-2257.
42. Dybdahl M, Vogel U, Frentz G, et al. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol Biomarkers Prev 1999; 8:77-81.
43. Matullo G, Dunning AM, Guarrera S, et al. DNA repair polymorphisms and cancer risk in non-smokers in a cohort srudy. Carcinogenesis 2006; 27:997-1007.
44. Karahalil B, Kocabas NA, Ozcelik T. DNA repair gene polymorphisms and bladder cancer susceptibility in a Turkish population. Anticancer Res 2006; 26:4955-4958.
45. Shen M, Hung RJ, Brennan P, et al. Polymorphisms of the DNA repair genes XRCCl, XRCC3, XPD, interaction with environmental exposures, and bladder cancer risk in a case-control study in northern Italy. Cancer Epidemiol Biomarkers Prev 2003; 12:1234-1240.
46. Yu HP, Zhang XY, Wang XL, et al. DNA repair gene XRCC1 polymorphisms, smoking, and esophageal cancer risk. Cancer Detect Prev 2004; 28:194-199.
47. Xing DY, Tan W, Song N, et al. Ser326Cys polymorphism in hOGG1 gene and risk of esophageal cancer in a Chinese population. Int J Cancer 2001; 95:140-143.
48. Duell EJ, Millikan RC, Pirtman GS, et al. Polymorphisms in the DNA repair gene XRCCl and breast cancer. Cancer Epidemiol Biomarkers Prev 2001; 10:217-222.
49. Terry MB, Gammon MD, Zhang FF, et al. Polymorphism in the DNA repair gene XPD, polycyclic aromatic hydrocarbon-DNA adducts, cigarette smoking, and breast cancer risk. Cancer Epidemiol Biomarkers Prev 2004; 13:2053-2058.
50. Healey CS, Dunning AM, Teare MD, et al. A common variant in BRCA2 is associated with both breast cancer risk and prenatal viability. Nat Genet 2000; 26:362-364.
51. Thacker J. The RAD51 gene family, genetic instability and cancer. Cancer Lett 2005; 239:125-135.
52. Beiner ME, Rosen B, Fyles A, et al. Endometrial cancer risk is associated with variants of the mismatch repair genes MLHl and MSH2. Cancer Epidemiol Biomarkers Prev 2006; 15:1636-1640.
53. Esteller M, Hamilton SR, Burger PC, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Res 1999; 59:793-797.
54. Esteller M, Toyota M, Sanchez-Cespedes M, et al. Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is associated with G to A mutations in K-ras in colorectal tumorigenesis. Cancer Res 2000; 60:2368-2371.
55. Esteller M, Risques RA, Toyota M, et al. Promoter hypermethylation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase is associated with the presence of G:C to A:T transition mutations in p53 in human colorectal tumorigenesis. Cancer Res 2001; 61:4689-4692.
56. Wolf P, Hu YC, Doffek K, et al. O(6)-Methylguanine-DNA methyltransferase promoter hypermethylation shirts the p53 mutational spectrum in non-small cell lung cancer. Cancer Res 2001; 61:8113-8117.
57. Chaney SG, Sancar A. DNA repair: enzymatic mechanisms and relevance to drug response. J Natl Cancer Inst 1996; 88:1346-1360.
58. Zeng-Rong N, Paterson J, Alperr L, et al. Elevated DNA repair capacity is associated with intrinsic resistance of lung cancer to chemotherapy. Cancer Res 1995; 55:4760-4764.
59. van de Vaart PJ, Belderbos J, de Jong D, et al. DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy. Int J Cancer 2000; 89:160-166.
60. Bosken CH, Wei Q> Amos CI, et al. An analysis of DNA repair as a determinant of survival in patients with non-small-cell lung cancet. J Natl Cancer Inst 2002; 94:1091-1099.
61. Garcia-Campelo R, Alonso-Curbera G, Anton Apaticio LM, et al. Pharmacogenomics in lung cancer: an analysis of DNA repair gene expression in patients treated with platinum-based chemotherapy. Expert Opin Pharmacother 2005; 6:2015-2026.
62. Moullan N, Cox DG, Angele S, et al. Polymorphisms in the DNA repair gene XRCC1, breast cancer risk, and response to radiotherapy. Cancer Epidemiol Biomarkers Prev 2003; 12:1168-1174.
63. Sakano S, Wada T, Matsumoto H, et al. Single nucleotide polymorphisms in DNA repair genes might be prognostic factors in muscle-invasive bladder cancer patients treated with chemoradiotherapy. Br J Cancer 2006; 95:561-570.
64. Suk R, Gurubhagavatula S, Park S, et al. Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients. Clin Cancer Res 2005; 11:1534-1538.
65. Shen MR, Jones IM, Mohrenweiser H. Nonconservative amino acid substitution variants exist at polymorphic frequency in DNA repair genes in healthy humans. Cancer Res 1998; 58:604-608.
66. Gurubhagavatula S, Liu G, Park S, et al. XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy. J Clin Oncol 2004; 22:2594-2601.
67. Camps C, Sanies C, Roig B, et al. Assessment of nucleotide excision repair XPD polymorphisms in the peripheral blood of gemcitabine/cisplatin- treated advanced non-small-cell lung cancer patients. Clin Lung Cancer 2003; 4:237-241.
68. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10:4939-4943.
69. Matullo G, Palli D, Peluso M, et al. XRCCl, XRCC3, XPD gene polymorphisms, smoking and (32)P-DNA adducts in a sample of healthy subjects. Carcinogenesis 2001; 22:1437-1445.
70. De las Penas R, Sanchez-Ronco M, Alberola V, et al. Polymorphisms in DNA repair genes modulate survival in cisplatin/gemcitabine-treated non-small-cell lung cancer patients. Ann Oncol 2006; 17:668-675.
71. Rosell R, Alberola A, Camps C, et al. Clinical outcome of gemcitabine (gem)/ cisplatin (cis)- vs docetaxel (doc)/cis-treated stage IV non-small cell lung cancer (NSCLC) patients (p) according to X-ray repair cross-complementing group 3 (XRCC3) polymorphism and age. J Clin Oncol 2006; 24:7055.
72. Li D, Frazier M, Evans DB, et al. Single nucleotide polymorphisms of RecQ1, RAD54L, and ATM genes are associated with reduced survival of pancreatic cancer. J Clin Oncol 2006; 24:1720-1728.
73. Sarries C, Haura EB, Roig B, et al. Pharmacogenomic strategies for developing customized chemotherapy in non-small cell lung cancer. Pharmacogenomics 2002; 3:763-780.
74. Youn CK, Kim MH, Cho HJ, et al. Oncogenic H-Ras up-regulates expression of ERCC1 to protect cells from platinum-based anticancer agents. Cancer Res 2004; 64:4849-4857.
75. Bellmunt J, Paz-Ares L, Cuello M, et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18:522-528.
76. Olaussen KA, Dunant A, Fouret P, et al. DNA repair by ERCCl in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991.
77. Rosell R, Taron M, Alberola V, et al. Genetic testing for chemotherapy in non-small cell lung cancer. Lung Cancer 2003; 41(suppl 1):S97-102.
78. Rosell R, Crino L, Danenberg K, et al. Targeted therapy in combination with gemcitabine in non-small cell lung cancer. Semin Oncol 2003; 30:19-25.
79. Taron M, Rosell R, Felip E, et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet 2004; 13:2443-2449.
80. Kennedy RD, Quinn JE, Mullan PB, et al. The role of BRCA1 in the cellular response to chemothefapy. J Natl Cancer Inst 2004; 96:1659-1668.
81. Wachters FM, Wong LS, Timens W, et al. ERCCl, hRad5L and BRCA1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemothetapy. Lung Cancer 2005; 50:211-219.
82. Rosell R, Lord RV, Taron M, et al. DNA repair and cisplatin resistance in non-small-cell lung cancer. Lung Cancer 2002; 38:217-227.
83. Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in cisplatin resistance in non-small-cell lung cancer. Cancer Control 2003; 10:297-305.
84. Zheng Z, Chen T, Li X, etal. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-808.
85. Balana C, Ramirez JL, Taron M, et al. O6-methyl-guanine-DNA methyltransferase methylation in serum and tumor DNA predicts response to 1,3-bis(2-chloroethyl)-1-nitrosourea but not to temozolamide plus cisplatin in glioblastoma multiforme. Clin Cancer Res 2003; 9:1461-1468.
86. Esteller M, Herman JG. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer. Oncogene 2004; 23:1-8.
87. Paz MF, Yaya-Tur R, Rojas-Marcos I, et al. CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clin Cancer Res 2004; 10:4933-4938.
88. Esteller M, Garcia-Foncillas J, Andion E, et al. Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 2000; 343:1350-1354.
89. Rosell R, Cecere F, Santarpia M, et al. Predicting the outcome of chemotherapy for lung cancer. Curr Opin Pharmacol 2006; 6:323-331.
90. Santarpia M, Altavilla G, Salazar F, et al. From the bench to the bed: individualizing treatment in non-small-cell lung cancer. Clin Transl Oncol 2006; 8:71-76.